T1	Participants 194 264	patients with unresectable stage IIIA and B non-small-cell lung cancer
T2	Participants 447 638	Eligible patients were treatment naive, and had stage IIIA and B unresectable non-small-cell lung cancer, Eastern Cooperative Oncology Group performance status 0/1, and normal organ function.
T3	Participants 901 913	388 patients
T4	Participants 1085 1107	141 patients enrolled,